Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

UGN-104

Phase 3Small molecule

UUroGen Pharma Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Upper Urinary Tract Urothelial CarcinomaRecruiting

Upper Urinary Tract Urothelial CarcinomaPhase 3

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Upper Urinary Tract Urothelial Carcinoma

NCT06774131

Clinical

Trials by Indication[1]

Upper Urinary Tract Urothelial Carcinoma1 trial

A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

Recruiting·UUroGen Pharma Ltd.·Phase 3·NCT06774131·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for UGN-104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UGN-104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UGN-104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UroGen Pharma Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUroGen Pharma Ltd.

Related News